A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

37 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2016-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary purpose is to assess whether there is transfer of Certolizumab Pegol (CZP) from pregnant women receiving treatment with Cimzia® across the placenta to infants by evaluating the concentration of CZP in the plasma of infants at birth.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers

NCT02154425

Axial Spondyloarthritis (AxSpA) Non-radiographic Evidence-AxSpA Ankylosing Spondylitis +3 more

COMPLETED PHASE1

Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis

NCT06940661

Granulomatosis With Polyangiitis

NOT_YET_RECRUITING PHASE2

Study of Intravenously Administered Anti-LIGHT Monoclonal Antibody CBS001 in Healthy Volunteers

NCT05323110

Chronic Inflammatory Disease

TERMINATED PHASE1

Rituximab Plus Corticosteroids in Non-infectious Active Mixed Cryoglobulinemia Vasculitis

NCT02556866

Cryoglobulinemia Systemic Vasculitis

TERMINATED PHASE2

Apremilast Pregnancy Exposure Registry

NCT02775500

Psoriatic Arthritis Psoriasis

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Axial Spondyloarthritis (AxSpA) Non-radiographic Evidence-AxSpA Ankylosing Spondylitis Crohn's Disease Psoriatic Arthritis Rheumatoid Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pharmacokinetic samples

Pharmacokinetic (PK) samples will be taken from the mother at Day 0 within 24 hours before/after delivery, from the infant within 24 hours after birth, at Week 4 and Week 8 and from the umbilical cord within one hour after delivery.

Included are mothers who decided to continue on, or to start treatment with certolizumab pegol (CZP) for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label.

Group Type EXPERIMENTAL

Blood sampling from mother

Intervention Type PROCEDURE

A blood sample from the mother will be taken within 24 hours before/after the delivery.

Blood sampling from infant

Intervention Type PROCEDURE

Blood samples from the infant will be taken within 24 hours after birth, at Week 4 and at Week 8.

Blood sampling from umbilical cord

Intervention Type PROCEDURE

A blood sample from the umbilical cord will be taken directly (within 1 hour ) after delivery.

Certolizumab Pegol

Intervention Type BIOLOGICAL

Mothers who decided to continue on, or to start treatment with, CZP for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label.

* Active Substance: Certolizumab Pegol
* Pharmaceutical Form: Solution for injection
* Concentration: 200 mg/ml
* Route of Administration: Subcutaneous Use

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood sampling from mother

A blood sample from the mother will be taken within 24 hours before/after the delivery.

Intervention Type PROCEDURE

Blood sampling from infant

Blood samples from the infant will be taken within 24 hours after birth, at Week 4 and at Week 8.

Intervention Type PROCEDURE

Blood sampling from umbilical cord

A blood sample from the umbilical cord will be taken directly (within 1 hour ) after delivery.

Intervention Type PROCEDURE

Certolizumab Pegol

Mothers who decided to continue on, or to start treatment with, CZP for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label.

* Active Substance: Certolizumab Pegol
* Pharmaceutical Form: Solution for injection
* Concentration: 200 mg/ml
* Route of Administration: Subcutaneous Use

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cimzia®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* An IRB/IEC approved written Informed Consent form for the maternal subject and her infant(s) is signed and dated by the subject. Where applicable, the written Informed Consent form with respect to the infant(s) is also signed and dated by the holder of parental rights as designated by the maternal subject
* Subject is considered reliable and capable of adhering to the protocol and visit schedule according to the judgment of the Investigator
* Subject is female ≥18 years at the time of informed consent
* Subject is ≥30 weeks pregnant with a singleton or twins at the time of informed consent
* Subject is being treated with Certolizumab Pegol (CZP) per the current approved prescribing Information
* Subject started or decided to continue treatment with CZP independently from and prior to participating in this study and in accordance with the treating physician
* Subject expects to receive CZP until at least 35 days prior to expected delivery (date of injection counted as Day 1)

Additional criteria to be confirmed prior to first sample from infant at Visit 2 (delivery/birth):

* Subject delivers a live born infant(s) at or near term (≥34 weeks gestation )
* Subject received CZP within 35 days before delivery (date of injection counted as Day 1)
* Subject has not received contraindicated medication

Exclusion Criteria

* Subject has participated in a study of an investigational medicinal product (IMP) or medical device within the previous 30 days or 5 half-lives (whichever is longer) prior to Screening or is currently participating in another study of an IMP or medical device - unless the study is UCB UP0016 \[NCT02154425\] or a registry study
* Subject has any obstetrical or psychiatric condition, or she or her infant(s) has any medical condition that, in the opinion of the Investigator, could jeopardize or would compromise the subject's ability to participate in this study or the outcome of the pregnancy
* Subject has history of chronic alcohol abuse or drug abuse during pregnancy
* Subject has any pregnancy-related clinically significant abnormality noted on obstetric ultrasound, or other imaging assessment, or the subject has significant laboratory abnormalities during her pregnancy, as judged by the Investigator
* Subject is taking or has taken any medication with strong positive evidence of a human fetal risk of teratogenicity (e.g., methotrexate or leflunomide) during pregnancy
* Subject has evidence of a condition suggesting chronic or acute uteroplacental insufficiency such as intrauterine growth restriction, severe maternal hypertensive disorders of pregnancy, or abruption
* Subject has a documented history of primary or secondary antiphospholipid syndrome or hypercoagulable state
* Subject has received treatment with any biological therapeutic agent, including anti-TNFs other than certolizumab pegol (CZP), during pregnancy
* Subject has previously participated in this study
* Subject has a positive or indeterminate QuantiFERON®-TB GOLD In Tube test at Screening. In case of indeterminate result, a retest is allowed if time permits; 2 results of indeterminate require exclusion of the subject
* Subject with known tuberculosis (TB) infection, at high risk of acquiring TB infection, or latent TB infection (LTB). If tested within the 6 months prior to Screening and the test was negative for TB, and there is no change in the subject's clinical status, nor social, family, or travel history, there is no need for an additional TB testing at Screening

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No